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Abstract
Purpose Severe combined immunodeficiency (SCID) en-
compasses a group of disorders characterized by reduced or
absent T-cell number and function and identified by newborn
screening utilizing T-cell receptor excision circles (TRECs).
This screening has also identified infants with T lymphopenia
who lackmutations in typical SCID genes.We report an infant
with low TRECs and non-SCID T lymphopenia, who proved
upon whole exome sequencing to have Nijmegen breakage
syndrome (NBS).
Methods Exome sequencing of DNA from the infant and his
parents was performed. Genomic analysis revealed deleteri-
ous variants in the NBN gene. Confirmatory testing included
Sanger sequencing and immunoblotting and radiosensitivity
testing of patient lymphocytes.
Results Two novel nonsense mutations in NBN were identi-
fied in genomic DNA from the family. Immunoblotting
showed absence of nibrin protein. A colony survival assay
demonstrated radiosensitivity comparable to patients with
ataxia telangiectasia.
Conclusions Although TREC screening was developed to
identify newborns with SCID, it has also identified T lympho-
penic disorders that may not otherwise be diagnosed until later
in life. Timely identification of an infant with T lymphopenia
allowed for prompt pursuit of underlying etiology, making
possible a diagnosis of NBS, genetic counseling, and early
intervention to minimize complications.
Keywords Nijmegen breakage syndrome . TREC . SCID .
exome sequencing . nibrin . T lymphopenia
Introduction
Severe combined immunodeficiency (SCID) refers to a group
of life-threatening fatal, congenital disorders characterized by
absent or reduced T-cell number and reduced or non-
functional B-cells. An early diagnosis of SCID allows for
avoidance of exposure to infections, live virus vaccines and
non-irradiated blood products, and also makes possible early
hematopoietic stem cell transplantation (HSCT) or other im-
mune system restoring treatments, adenosine deaminase en-
zyme replacement, or gene therapy [1].
Since beginning in 2008 in Wisconsin, newborn screening
for SCID has been implemented in 23 states in the U.S., as
well as in the Navajo Nation [2]. The assay employs PCR
quantification of circular DNA byproducts of T-cell receptor
gene rearrangement, T-cell receptor excision circles (TRECs).
Although TRECs have no identifiable function, their presence
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serves as a marker for the maturation of T-cells [3].
Insufficiency of TRECs characterizes SCID and other T-
lymphopenic disorders including complete DiGeorge
Syndrome [4] and some cases of ataxia telangiectasia (AT) [5].
Like AT, Nijmegen breakage syndrome (NBS) [6–9] (former-
ly known as an AT Variant 1) is a disorder of DNA repair asso-
ciated with chromosomal instability and immune compromise
that may be identified through TREC screening. Herein, we de-
scribe a baby with a complex perinatal history and low TRECs
near birth. Flow cytometry confirmed modest T-lymphopenia.
Whole exome sequencing identified heterozygous mutations in
NBN, the gene that encodes nibrin, a component of a molecular
complex involved in the early recognition and subsequent repair
of DNA damage [10]. Nibrin was absent from nuclear lysates on
immunoblots, and the patient’s cells were hypersensitive to ion-
izing radiation by colony survival assay [11, 12].
Case Report
A 41-week gestational age male (NBS20LA), weighing 2860
grams, was born via normal vaginal delivery to a 23-year-old,
gravida 1, paragravida 0 mother following prenatal identifica-
tion of increased cerebrospinal fluid on ultrasound. Postnatally,
the infant was hospitalized for 1 week for meconium aspira-
tion. By 4 weeks of age progressive hydrocephalus required a
ventriculo-peritoneal shunt. At 17 weeks, he was hospitalized
for a presumed urinary tract infection; renal ultrasound showed
left hydronephrosis. During the first year of life he also exhib-
ited developmental delay and failure to thrive with weight and
length for age persistently below the 3rd percentiles and head
circumference at 8 months of age below the 2nd percentile.
At 3 weeks of age, SCID newborn screening results were
interpreted as Bincomplete^: TREC, 13 copies/mcL (normal
>25) and actin control, 9,510 copies/mcL (normal >10,000).
Repeat screening was Bpositive^: TREC, 12 copies/mcL and
actin, 19,800 copies/mcL. Subsequent flow cytometry at
6 weeks of life demonstrated persistent T-lymphopenia and
elevated NK cell percentages and numbers (Table 1).
Targeted sequencing of SCID associated genes ADA, AK2,
CD3D, CD3zeta, DCLRE1C, ILRG, IL7R, JAK3, LIG4,
NHEJ1, PNP, PTPRC, RAC2, RAG1, RAG2, RMRP, and
ZAP70 (GeneDx, Gaithersburg, MD) and enzyme assays for




Informed consent was obtained for research, including cellular
immune studies and whole exome sequencing (WES), for the
infant and both parents under approved protocols at Children’s
Hospital Los Angeles (CHLA) and the University of
California San Francisco (UCSF). Genomic DNA from
EDTA-anticoagulated whole blood was prepared using a
Gentra Puregene Blood kit (Qiagen USA: Germantown, MD).
Exome Sequencing and Analysis
WES was performed as previously described [5]. Briefly, li-
braries prepared by ligating TruSeq adaptors (Illumina: San
Diego, CA) to genomic DNA fragments of 200–300 bp were
enriched with 10 cycles of PCR, pooled and submitted to exon
capture using a Roche Nimblegen version 3.0 capture array.
After 10 additional amplification cycles, 100 bp paired end
sequence reads were generated (HiSeq2000, llumina), yield-
ing 3.8 % duplicates and a mean of >100 reads covering the
targeted regions, with >95 % of target regions having ≥10
reads.
Reads were aligned against GRCh37 (Aug 2009 release)
using BWA (v0.6.2) [13]. The results were converted to
BAM, sorted by coordinate, indexed, and marked for PCR
duplicate reads using the Picard toolkit (v 1.81) (http://
picard.sourceforge.net). Local realignment was performed
around known indel locations, and base quality scores were
re-calibrated using GATK (v 2.6.5) [14, 15].
Variants were called using GATK UnifiedGenotyper and
freebayes (vesion 0.9.10) [16]. GATK variant quality scores
were re-calibrated by VQSR (Variant Quality Score
Recalibration) using the trio of exomes in this report, as well
as 65 others sequenced at our site. HapMap v3.3 [17], 1000
genomes high confidence SNPs (phase1 v3 2010-11-23) and
Omni chip array sets were used as training data, and to pro-
vided truth sites for SNPs, while the Mills dataset [18] from
the 1000 genomes was used for indels, using a truth sensitivity
cutoff of 99 %. Variant annotation (including region, effect,
allele frequency, disease phenotype annotation, and conserva-
tion) was performed using our custom tool Varant (http://
compbio.berkeley.edu/proj/varant/).
Particular attention was given to high-confidence, rare,
likely-damaging, protein-altering variants in genes associated
with primary cellular immunodeficiency [19] and to those
conforming to models of autosomal or X-linked recessive in-
heritance in the family, or de novo mutations that may be
dominant. Candidate variants in NBN were given priority
and confirmed by Sanger sequencing.
Immunoblotting
Peripheral blood lymphoblastoid cell lines (LCL) from the
patient NBS20LA and controls were made with Epstein-Barr
virus as described [11], and 50 μg of nuclear protein lysate
from each was electrophoresed on a 6 % SDS-polyacrylamide
gel (PAGE), blotted onto PVDF membrane (BioRad,
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Hercules, CA) and incubated with antibodies to nibrin
(Novus, NB100-143 at 1:5000, Littleton, CO) overnight at
4 °C. The immunoblots were subsequently incubated with
an HRP-conjugated anti-rabbit secondary antibody at room
temperature for 40 min for detection by enhanced chemilumi-
nescence (ECL) (Amersham Pharmacia, Piscataway, NJ).
Under the conditions of the assay, as little as 1 μg of nibrin
protein could be detected. p84 was used as a loading control
(Genetex GTX70220 at 1:3000). On the same blot, MRE11
and Rad50 were also measured (Novus 100–142 at 1:15,000
and Novus 100–154 at 1:500, respectively).
Peripheral blood lymphocytes from the patient NBS20LA
and controls were immortalized with Epstein-Barr virus as pre-
viously described [11], and 50 μg of nuclear lysate protein from
the each lymphoblastoid cell line (LCL) was electrophoresed on
a 6 % SDS-polyacrylamide gel (PAGE), blotted onto PVDF
membrane (BioRad, Hercules, CA) and incubated with antibod-
ies to nibrin andDNA repair proteinsMRE11, RAD50 andATM
(Novus, Littleton, CO) overnight at 4 °C. The immunoblots were
subsequently incubated with an HRP-conjugated anti-rabbit sec-
ondary antibody at room temperature for 40 min for detection by
enhanced chemiluminescence (ECL) (Amersham Pharmacia,
Piscataway, NJ). Under the conditions of the assay, as little as
1 μg of nibrin protein can be detected.
Colony Survival Assay
LCLs from wild type (healthy controls), individuals with AT
(radiosensitive controls), and NBS20LA were maintained in
RMPI 1640 medium with 10 % fetal bovine serum and 1 %
penicillin-streptomycin-L-glutamine [12]. After plating into
paired 96-well trays, one of each pair was irradiated with 1
Gray. After incubation at 37 °C for 2 weeks, the trays were
stained with 0.1 % 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide. Individual wells with at least one colony
composed of >32 cells (i.e., >5 divisions) were scored as pos-
itive. The number of positive wells in irradiated- versus non-
irradiated plates was compared to determine the survival frac-
tion. Results were compared to measurements performed by
Sun et al. using 104 AT patients and 29 healthy controls [12].
Results
WES analysis by our Varant tool identified two nonsense mu-
tations inNBN on chromosome 8q21.3 in the patient, suggest-
ing a diagnosis of NBS. The patient and his father shared a
thymine to guanine transversion cDNA 842 T >G
(NM_002485.4(NBN):c.842 T>G) in exon 6, changing leu-
cine 281 to a stop codon (protein L281X) (ClinVar Provisional
Accession: SCV000196640), while the infant and mother
shared a cytosine to thymine transition cDNA 1030C>T
(NM_002485.4(NBN):c.1030C>T) in exon 9, changing
glutamine 344 to a stop codon (Q344X) (ClinVar
Provisional Accession: SCV000196641) [20]. A rare X-
linked CD40LG gene variant noted in our patient and mother
NM_000074 (CD40LG):c.542G>C (chrX: 135741330, G>
C; R181P in CD40LG) was predicted damaging by
PolyPhen-2 software [21], but was inconsistent with the pa-
tient’s phenotoype. No other high quality DNAvariants in the
targeted exome regions were as consistent with the phenotype.
Neither variant had been reported in other patients with NBS
nor in the 1000 genomes [22], ESPDB [23] or dbSNP (v137)
[24] databases. The patient’s paternally inherited allele carried
L281X, while his maternally inherited allele carried Q344X.
Confirmatory Sanger sequencing was performed by the
CLIA-approved Molecular Genetics Laboratory at the
University of California Los Angeles School of Medicine.
An immunoblot showed no detectable nibrin protein in
NBS20LA (Fig. 1, penultimate lane). Interestingly, MRE11
and Rad50 protein levels were also reduced; this reflects the
instability of the MRE11-Rad50-nibrin (MRN) complex
whenever nibrin is absent. Lane 2 contains LCL protein from
an AT patient whose cell lines were radiosensitive in Fig. 2.
ATM protein was absent in the ATM LCL, but was present in
NBS20LA (not shown). All other LCLs in Fig. 1 were from
healthy individuals and showed normal amounts of MRN-
complex proteins and the loading control, p84. These findings
provided functional confirmation that the patient’s NBN vari-
ants were both null mutations that abrogated protein expres-
sion, and that his cells scored as radiosensitive.
Discussion
Although the primary goal of newborn screening with TRECs
has been the pre-symptomatic diagnosis of SCID, thereby
allowing early intervention, this screening has also identified
individuals with non-SCID T-lymphopenia. In California, the
first 2 years of newborn screening for SCID identified 50
Fig. 1 Immunoblot allows comparison of nibrin (NBS), MRE11 and
Rad50 protein levels in an NBS cell line (NBS20LA) to wild type and
ATcells. Note absence of nibrin in NBSLCL. Protein loading control was
p84
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infants with T-lymphopenia, defined as <1500 Tcells/mcL: 11
had typical SCID, five had idiopathic T-lymphopenia or var-
iant SCID (defined as significant T cell defects without muta-
tion in known SCID genes), eight had partial and one had
complete DiGeorge syndrome, four had trisomy 21, and three
had AT [5]. Twenty-three patients had preterm birth or other
congenital anomalies [4].
Recently, exome sequencing was utilized to identify AT as
the cause of T-lymphopenia in two patients with positive SCID
screens [5]. In this same study retrospective analysis of older
AT patients suggested that approximately half of patients with
ATwill have a positive newborn SCID screen. NBS is a distinct
DNA breakage/chromosomal instability disorder caused by de-
fects in nibrin, part of the same DNA repair pathway as AT
mutated protein. The immune defects in AT and NBS are sim-
ilar and include impaired VDJ recombination, which affects T-
cell receptor and immunoglobulin rearrangement. T-
lymphopenia and decreased TRECs as seen in patients with
ATwould thus also be expected in patients with NBS.
In our patient, the TREC newborn screening for SCID was
positive, but an extensive search for SCID genemutations was
unrevealing. In contrast, exome sequencing revealed novel,
compound heterozygous NBN mutations that were associated
with absence of nibrin and radiosensitivity. A R181Pmissense
variant in CD40LG, the gene associated with X-linked hyper-
IgM syndrome, was also predicted to be damaging but was
inconsistent with the patient’s clinical and laboratory data in-
cluding absent nibrin and a total serum IgG concentration in
the normal range and positive IgG antibody responses to tet-
anus and H. influenzae b. Although it is not impossible for a
patient to have two primary immune disorders, NBN muta-
tions fully explain the low T cells, absent nibrin and cellular
radiosensitivity that establish the diagnosis of NBS in this
patient, while the features of CD40L deficient hyper-IgM syn-
drome are absent.
The clinical phenotype of NBS is variable. Most patients
are full term [7], but may have microcephaly at birth with
subsequent growth failure. Most patients meet early develop-
mental milestones but have varying degrees of intellectual
disability later in life [7, 25–27]. Perinatal hydrocephalus as
seen in our patient has been reported in two childrenwith NBS
[8]. Hydronephrosis, renal anomalies such as horseshoe or
dysplastic kidneys, skeletal anomalies such as clinodactyly
and partial syndactyly, café au lait spots and vitiligo have all
been seen, but are not constant features and are also found in
other conditions [8, 28]. It is therefore difficult to identify
NBS based on early clinical signs. Lymphoid malignancy af-
fects up to 40 % of patients with NBS by their 21st year [28].
Onset of malignancy can vary in these patients depending on
the mutation inherited and degree of nibrin dysfunction [28].
Most patients with NBS show some degree of immunode-
ficiency. In a review of 57 patients from the Polish Nijmegen
Breakage Syndrome Registry, 19 % had normal total serum
i mm u n o g l o b u l i n s , w h i l e 2 5 % h a d s e v e r e
hypogammaglobulinemia [29]. At least one IgG subclass
was deficient in all patients: 89 % IgG4, 73 % IgG2 and
54% IgG1. Similarly, our patient had variably low total serum
immunoglobulins that trended upward with age (Table 1), but
IgG3 and IgG4 remained low (data not shown). Specific anti-
body response after two H. influenza type b immunizations
was negative at 6 months, but positive at 10 months following
an additional immunization. Tetanus toxoid titers were posi-
tive by 6 months. Our patient’s absolute CD19+ B cells were
reduced during the first year of life, as seen in 72 % of Polish
registry patients [29]. In the Polish cohort, 84 % of patients
received immunoglobulin replacement therapy for frequent or
Fig. 2 Colony Survival Assay
for AT and NBS B
lymphoblastoid cell lines
showing that both the AT control
cells and those of patient
NBS20LA are in the
radiosensitive range, as defined
by Sun et al. 2002 [12]
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prolonged respiratory tract infections, which have not oc-
curred in our patient up to the present.
Lymphocyte subset analysis in NBS has shown decreased
T cells, with CD4+ T cells affected most severely [29]. This is
consistent with our patient’s findings (Table 1). The elevated
proportion of NK cells seen in our patient was also noted
previously in 25 out of 40 patients [30].
The treatment of choice for SCID is most often HSCT. To
date, however, there is limited experience with HSCT in pa-
tients with NBS [31]. Indications for attempting transplanta-
tion have included severe immunodeficiency and hematologic
malignancy; pre-emptive HSCT has not been reported. Of
particular concern has been the use of DNA-damaging che-
motherapeutic conditioning regimens and the potential to in-
duce de novo malignancies in patients with a pre-existing
DNA repair deficit. There has been some success with re-
duced intensity pre-HSCT conditioning regimens, but studies
to date are limited by their retrospective nature, small sample
size and relatively short term follow-up.
Conclusions
With widespread adoption of TREC screening for SCID, NBS
may be identified prospectively, enabling the population inci-
dence and natural history to be better understood. NBS has
been reported primarily in Eastern Europeans, where founder
mutations occur [28]. Our case expands our appreciation of
the associat ion of NBS with hydrocephalus and
hydronephrosis and illustrates the utility of WES as applied
to diagnose the underlying cause of idiopathic T lymphopenia
found by TREC screening. There are more than 200 known
genetic defects for primary immunodeficiency [19, 32], and
testing of individual genes can be costly and time intensive.
WES resulted in prompt detection of two nonsense mutations
in NBN and definitive diagnosis in our patient, who presented
with atypical features of NBS. Establishing the diagnosis
allowed avoidance of live virus vaccines and exposure to ion-
izing radiation, as well as anticipatory monitoring for serious
infections and malignancy.
Trimethoprim/sulfamethoxazole was started to prevent
Pneumocystis jiroveci pneumonia; however he has not re-
ceived immunoglobulin infusions or HSCT. Exome sequenc-
ing of the parents also established the NBN mutations as
inherited versus de novo and allowed for accurate and infor-
mative counseling regarding the risk of future offspring
inheriting both affected genes and having NBS. The parents
were informed that other family members could be carriers of
these same mutations.
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